Total Payments
$84,806
2021 Payments
$8,300
Companies
7
Transactions
106
Medicare Patients
324
Medicare Billing
$32,725
Payment Breakdown by Category
Consulting$63,155 (74.5%)
Travel$8,528 (10.1%)
Research$7,200 (8.5%)
Other$2,990 (3.5%)
Food & Beverage$2,906 (3.4%)
Education$27.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $63,155 | 15 | 74.5% |
| Travel and Lodging | $8,528 | 34 | 10.1% |
| Unspecified | $7,200 | 1 | 8.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,990 | 1 | 3.5% |
| Food and Beverage | $2,906 | 54 | 3.4% |
| Education | $27.00 | 1 | 0.0% |
Payments by Type
General
$77,606
105 transactions
Research
$7,200
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $27,308 | 44 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $17,868 | 13 | $0 (2020) |
| GENZYME CORPORATION | $15,751 | 17 | $0 (2019) |
| GlaxoSmithKline, LLC. | $7,303 | 8 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,200 | 1 | $0 (2021) |
| Genentech USA, Inc. | $5,669 | 15 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $3,707 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $8,300 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($7,200) |
| 2020 | $9,282 | 5 | GlaxoSmithKline, LLC. ($6,584) |
| 2019 | $32,638 | 54 | Regeneron Healthcare Solutions, Inc. ($10,316) |
| 2018 | $21,972 | 26 | AstraZeneca Pharmaceuticals LP ($8,041) |
| 2017 | $12,615 | 19 | AstraZeneca Pharmaceuticals LP ($8,424) |
All Payment Transactions
106 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/12/2021 | Genentech USA, Inc. | Xolair (Biological) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Immunology | ||||||
| 04/01/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $7,200.00 | Research |
| Study: A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) | ||||||
| 09/24/2020 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,725.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/16/2020 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Consulting Fee | Cash or cash equivalent | $973.00 | General |
| Category: Respiratory | ||||||
| 04/18/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| Category: RESPIRATORY | ||||||
| 04/18/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | Cash or cash equivalent | $53.70 | General |
| Category: RESPIRATORY | ||||||
| 04/18/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | Cash or cash equivalent | $30.11 | General |
| Category: RESPIRATORY | ||||||
| 12/07/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $53.93 | General |
| Category: RESPIRATORY | ||||||
| 12/07/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $47.81 | General |
| Category: RESPIRATORY | ||||||
| 12/07/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $44.13 | General |
| Category: RESPIRATORY | ||||||
| 12/06/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | In-kind items and services | $151.16 | General |
| Category: RESPIRATORY | ||||||
| 11/27/2019 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | In-kind items and services | $422.61 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2019 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Immunology | ||||||
| 08/09/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $50.57 | General |
| 08/09/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | Cash or cash equivalent | $46.05 | General |
| 08/09/2019 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $38.00 | General |
| 06/10/2019 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $112.11 | General |
| Category: Immunology | ||||||
| 05/16/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: Respiratory | ||||||
| 05/01/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: Respiratory | ||||||
| 04/26/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Travel and Lodging | In-kind items and services | $419.61 | General |
| Category: Respiratory | ||||||
| 04/26/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Travel and Lodging | In-kind items and services | $192.66 | General |
| Category: Respiratory | ||||||
| 04/26/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Travel and Lodging | In-kind items and services | $101.34 | General |
| Category: Respiratory | ||||||
| 04/26/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $45.45 | General |
| Category: Respiratory | ||||||
| 04/26/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Respiratory | ||||||
| 04/26/2019 | AstraZeneca Pharmaceuticals LP | FASENRA (Drug) | Food and Beverage | In-kind items and services | $31.81 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) | Takeda Pharmaceuticals U.S.A., Inc. | $7,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 21 | 21 | $11,130 | $1,569 |
| 2021 | 8 | 179 | 1,020 | $113,359 | $22,759 |
| 2020 | 6 | 124 | 134 | $46,128 | $8,397 |
Total Patients
324
Total Services
1,175
Medicare Billing
$32,725
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 21 | $11,130 | $1,569 | 14.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 42 | 67 | $31,985 | $7,462 | 23.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 36 | 45 | $14,595 | $3,100 | 21.2% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2021 | 13 | 367 | $13,582 | $3,015 | 22.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 21 | 21 | $14,623 | $2,790 | 19.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 18 | 25 | $11,683 | $2,386 | 20.4% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 14 | 454 | $13,166 | $1,765 | 13.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 16 | 16 | $7,225 | $1,137 | 15.7% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 19 | 25 | $6,500 | $1,105 | 17.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 33 | 35 | $15,646 | $2,781 | 17.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 38 | 41 | $12,635 | $2,521 | 20.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $9,432 | $1,604 | 17.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 15 | $4,645 | $878.68 | 18.9% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2020 | 11 | 11 | $2,816 | $479.35 | 17.0% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2020 | 16 | 18 | $954.00 | $131.99 | 13.8% |
About Dr. Aidan Long, MD
Dr. Aidan Long, MD is a Allergy & Immunology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1841280039.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Aidan Long, MD has received a total of $84,806 in payments from pharmaceutical and medical device companies, with $8,300 received in 2021. These payments were reported across 106 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($63,155).
As a Medicare-enrolled provider, Long has provided services to 324 Medicare beneficiaries, totaling 1,175 services with total Medicare billing of $32,725. Data is available for 3 years (2020–2022), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location Boston, MA
- Active Since 10/27/2005
- Last Updated 04/16/2014
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1841280039
Products in Payments
- FASENRA (Drug) $18,868
- DUPIXENT (Drug) $15,751
- DUPIXENT (Biological) $12,041
- NUCALA (Biological) $7,303
- DUPIXENT DUPILUMAB INJECTION (Biological) $5,827
- Xolair (Biological) $5,669
- XOLAIR (Biological) $3,346
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Allergy & Immunology Doctors in Boston
Dr. Wanda Phipatanakul, Md, Ms, MD, MS
Allergy & Immunology — Payments: $686,630
Allergy & Immunology $686,630
Dr. Michael Pistiner, M.d, M.D
Allergy & Immunology — Payments: $105,999
Allergy & Immunology $105,999
Dr. Kari Nadeau, M.d., Ph.d, M.D., PH.D
Allergy & Immunology — Payments: $98,140
Allergy & Immunology $98,140
Dr. Jeffrey Gelfand, Md, MD
Allergy & Immunology — Payments: $96,200
Allergy & Immunology $96,200
Wayne Marasco, M.d., Ph.d, M.D., PH.D
Allergy & Immunology — Payments: $40,283
Allergy & Immunology $40,283
Dr. Richard Moscicki, Md, MD
Allergy & Immunology — Payments: $24,156
Allergy & Immunology $24,156